Illumina, Inc.

ILMN Healthcare Diagnostics & Research

Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024.

Revenue
+4.15%
EPS
+49.0%
Free cash flow
+49.8%
Total debt
+80.0%

Quarter to September 2026, against a year earlier

209.82 16.72 −7.38%
Market cap
$31.5B
P/E
35.6×
Fwd P/E
46.4×
Dividend yield
—
F-score
8/9
Altman Z
4.39
Beneish M
−2.51
Dividend safety
n/a

Illumina, Inc. (ILMN) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Illumina, Inc. (ILMN) trades at a P/S ratio of 7.0×. Over the past ten years it has ranged from 2.6× (April 2025) to 22.5× (February 2021); the current reading is higher than 31% of that period. That is above the Diagnostics & Research industry median of 4.2× and above the Healthcare sector median of 3.5×.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2025 4.7× (3.68%)
FY2024 4.9× 2.54%
FY2023 4.7× (29.84%)
FY2022 6.8× (45.44%)
FY2021 12.4× (24.91%)
FY2020 16.5× 22.00%
FY2019 13.5× 4.05%
FY2018 13.0× 11.30%
FY2017 11.7× 47.86%
FY2016 7.9× (35.28%)

Quarterly newest first

Period P/S ratio Change
Sep 2026 9.1× 54.11%
Jun 2026 5.9× 37.65%
Mar 2026 4.3× (8.29%)
Dec 2025 4.7× 38.14%
43 more quarters

Against its own ten years

Low 2.6× High 22.5×
Ten-year median 10.4×
Current reading's percentile 34

P/S ratio against peers

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on ILMN